XML 57 R36.htm IDEA: XBRL DOCUMENT v3.25.1

SEGMENTS (Tables)

12 Months Ended

Dec. 31, 2024

SEGMENTS [Abstract]

Summarized Financial Information Concerning Reportable Segments

Summarized financial information concerning reportable segments is shown in the following tables:

Year Ended December 31, 2024
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	415,806			$	10,505			$	426,311
Cost of product revenue			195,605				11,296				206,901
Research and development			1,813				-				1,813
Plasma center operating expenses			-				4,245				4,245
Selling, marketing and distribution			18,683				-				18,683
Depreciation and amortization expense			4,827				3,218				8,045
General and administrative expense			26,001				-				26,001
Other expense, net			(178	)			(5	)			(183	)
Income (loss) before taxes			173,138				(5,041	)			168,097
Expenditures for additions to long-lived assets			8,352				223				8,575
Total assets			289,297				30,477				319,774
Reconciliation of revenues:
Segment revenue										$	426,311
License revenue (see Note 2 - Revenue Recognition)											143
Consolidated revenues										$	426,454
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	18,683
Segment general and administrative expense											26,001
Corporate general and administrative expense (a)											29,440
Consolidated selling, general and administrative expense										$	74,124
Reconciliation of income (loss) before taxes:
Segment income before taxes										$	168,097
License revenue											143
Unallocated interest expense, primarily related to interest on senior debt (see Note 7)											(13,930	)
Loss on extinguishment of debt (see Note 7)											(1,243	)
Unallocated interest income											2,087
Corporate general and administrative expense (a)											(29,440	)
Consolidated income before taxes										$	125,714
Reconciliation of total assets:
Total segment assets										$	319,774
Corporate (b)											168,904
Consolidated total assets										$	488,678

(a) -
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.

(b) -
Primarily consists of cash and deferred tax assets.

Year Ended December 31, 2023
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	249,738			$	8,334			$	258,072
Cost of product revenue			161,157				8,116				169,273
Research and development			3,300				-				3,300
Plasma center operating expenses			-				4,266				4,266
Selling, marketing and distribution			18,407				-				18,407
Depreciation and amortization expense			5,156				3,176				8,332
General and administrative expense			18,625				-				18,625
Income (loss) before taxes			47,267				(4,049	)			43,218
Expenditures for additions to long-lived assets			2,952				1,819				4,771
Total assets			246,719				34,733				281,452
Reconciliation of revenues:
Segment revenue										$	258,072
License revenue (see Note 2 - Revenue Recognition)											143
Consolidated revenues										$	258,215
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	18,407
Segment general and administrative expense											18,625
Corporate general and administrative expense (a)											21,988
Consolidated selling, general and administrative expense										$	59,020
Reconciliation of income (loss) before taxes:
Segment income before taxes										$	43,218
License revenue											143
Unallocated interest expense, primaril related to interest on senior debt (see Note 7)											(25,027	)
Loss on extinguishment of debt (see Note 7)											(26,174	)
Unallocated interest income											1,589
Corporate general and administrative expense (a)											(21,988	)
Consolidated income before taxes										$	(28,239	)
Reconciliation of total assets:
Total segment assets										$	281,452
Corporate (b)											47,730
Consolidated total assets										$	329,182

(a) -
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.

(b) -
Primarily consists of cash.

Year Ended December 31, 2022
(in thousands)		ADMA BioManufacturing				Plasma Collection Centers				Total
Revenues		$	144,070			$	9,867			$	153,937
Cost of product revenue			108,882				9,933				118,815
Research and development			3,614				-				3,614
Plasma center operating expenses			-				17,843				17,843
Selling, marketing and distribution			13,667				-				13,667
Depreciation and amortization expense			4,709				2,404				7,113
General and administrative expense			16,312				-				16,312
Income (loss) before taxes			374				(17,911	)			(17,537	)
Expenditures for additions to long-lived assets			5,247				8,664				13,911
Total assets			238,159				37,071				275,230
Reconciliation of revenues:
Segment revenue										$	153,937
License revenue (see Note 2 - Revenue Recognition)											143
Consolidated revenues										$	154,080
Reconciliation of selling, general and administrative expense:
Segment selling, marketing and distribution expense										$	13,667
Segment general and administrative expense											16,312
Corporate general and administrative expense (a)											22,479
Consolidated selling, general and administrative expense										$	52,458
Reconciliation of income (loss) before taxes:
Segment income before taxes										$	(17,537	)
License revenue											143
Unallocated interest expense, primaril related to interest on senior debt (see Note 7)											(19,276	)
Loss on extinguishment of debt (see Note 7)											(6,670	)
Other expense											(85	)
Corporate general and administrative expense (a)											(22,479	)
Consolidated income before taxes										$	(65,904	)
Reconciliation of total assets:
Total segment assets										$	275,230
Corporate (b)											73,231
Consolidated total assets										$	348,461

(a) -
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.

(b) -
Primarily consists of cash.

Net Revenues According to Geographic Area

Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:

		Year Ended December 31, 2024
		ADMA BioManufacturing				Plasma Centers				Total Segment Revenue				License Revenue				Consolidated Revenue
United States		$	400,336			$	9,669			$	410,005			$	143			$	410,148
International			15,470				836				16,306				-				16,306
Total revenues		$	415,806			$	10,505			$	426,311			$	143			$	426,454

		Year Ended December 31, 2023
		ADMA BioManufacturing				Plasma Centers				Total Segment Revenue				License Revenue				Consolidated Revenue
United States		$	237,454			$	7,284			$	244,738			$	143			$	244,881
International			12,284				1,050				13,334				-				13,334
Total revenues		$	249,738			$	8,334			$	258,072			$	143			$	258,215

		Year Ended December 31, 2022
		ADMA BioManufacturing				Plasma Centers				Total Segment Revenue				License Revenue				Consolidated Revenue
United States		$	136,827			$	9,457			$	146,284			$	143			$	146,427
International			7,243				410				7,653				-				7,653
Total revenues		$	144,070			$	9,867			$	153,937			$	143			$	154,080

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration